Theravance Biopharma, Inc. Concurrent Ordinary Shares and Convertible Senior Notes Offerings
Davis Polk advised the joint book-running managers in connection with a $100.1 million SEC-registered offering of 3,850,000 ordinary shares of Theravance Biopharma, Inc. The ordinary…